March 27 (Reuters) - Walgreen will pay more than

$2.85 million to settle whistleblower allegations that the

pharmacy overbilled Medicaid programs in Georgia and

Massachusetts for generic medications, the U.S. Department of

Justice said on Thursday.

The settlement partially resolves claims against the

Walgreens Boots Alliance ( WBA ) unit brought under the federal, Georgia

and Massachusetts False Claims Act.

Walgreen pharmacies were accused of having from 2008 to 2023

submitted elevated "usual and customary" prices for some generic

medications to the MassHealth and Georgia Medicaid programs,

causing those programs to pay more for the medications than they

should have.

(Reporting by Jonathan Stempel in New York)